A pursuer of originality and inventiveness in China’s biotech industry
A practitioner of sustained innovation in global vaccine R&D arena
Founded in 2008, Beijing Health Guard Biotechnology, Inc. is a high-tech enterprise that is dedicated to R&D and commercialization of innovative vaccines featuring a structure-guided design approach, with an outstanding pipeline of HPV vaccines as its core assets.
As a top-tier player in the development of HPV vaccines in China, Beijing Health Guard has been strengthening its innovation capacity through continuous in-house innovation. As of today, Beijing Health Guard has been granted 33 invention patents. Several key technology platforms have been established, including structure-guided antigen design platform, protein engineering and expression platform, vaccine engineering platform and potency evaluation platform for recombinant protein vaccines with proficiency in utilizing E. coli, yeast and CHO cells as the expression system. Meanwhile, in order to sustain its innovation performance, the Company has established a platform for the development of mRNA-based vaccines and drugs.
With its headquarter and R&D center based in Longsheng Industrial Park, Beijing Economic and Technological Development Zone, the Company has a team of more than 200 talents, consisting of R&D professionals and management personnel. Core assets in our pipeline include a trivalent HPV vaccine, a nonavalent HPV vaccine (for female and male indications), 15-valent HPV vaccine, as well as a polyvalent norovirus vaccine, a RSV vaccine,a zoster vaccine, a HFMD vaccine and a polio vaccine, with the trivalent and nonavalent HPV vaccine for both indications in phase III studies which are among the first 3 domestic candidates entering pivotal trials.
Commercial production plant of the Company is located in No. 508, Xiangxian Road, the Airport Industrial Park of Dian Zhong New Area, Yunnan Province and has a construction area of 75,000 square meters for phase one construction. This commercial production plant will be equipped with facilities for both drug substance and drug product manufacturing, as well as warehouses, animal house, power center, sewage treatment station. Once the facilities are in full operation, it’s expected that the annual production capacity will be 30 million doses for the recombinant HPV vaccines and 5 million doses for the recombinant polyvalent norovirus vaccine, respectively.
The Company was listed on the NEEQ (National Equities Exchange and Quotations) on September 18th, 2015, with shares of the company trading under the ticker Health Guard and stock code 833575. The Company was selected as a constituent for the NEEQ Pharmaceutical Index, NEEQ Research and Development Index, NEEQ Market Making Index, NEEQ Innovation Component Index, NEEQ Component Index and NEEQ Active Stocks Index.
On March 15th, 2023, the Company was listed on the Beijing Stock Exchange, becoming the first IPO in the field of human vaccine on the Beijing Stock Exchange, and the first biotech listed under the market's 4th set of listing standards.
Since its inception, the company has been certified as a High and New Technology Enterprise (HNTE), a Beijing level science and technology R&D institution, a BDA Enterprise established by overseas high-level talents, a Rising star of BDA by Deloitte, a 2019 Zhongguancun Leading high-tech Enterprise and a 2020 Beijing Specialized and Special New SMES. Health Guard is a member of the China Association for Vaccines (CAV), Vaccine Clinical Research Branch of CAV and Nucleic acid vaccine branch of CAV.
Beijing Health Guard is "committed to improving the public’s health by providing safe, effective and innovative vaccines". On top of in-house innovation, Beijing Health Guard has been opening up to collaborations with domestic and foreign industry players. In January 2019, Health Guard and Liaoning Chengda Biotechnology Co., Ltd. entered into a collaboration agreement on the development and commercialization of the 15-valent HPV vaccine candidate developed by Health Guard. In May 2021, Health Guard reached agreements with R-Pharm on the development and commercialization of Health Guard’s nonavalent HPV vaccine in Russia.
In order to better serve the global public health and benefit more people, in addition to the ongoing efforts made to advance clinical study in females, the Company is the first to commence clinical trials of the nonavalent HPV vaccine in males. Meanwhile, the Company has been maintaining effective communication with Bill & Melinda Gates Foundation and PATH, and actively responding to WHO's initiative regarding HPV vaccine international procurement, so as to promote the internationalization process of HPV vaccine.
Health Guard is constructing a commercial production plant, which is located in the Airport Industrial Park of Dian Zhong New Area, Yunnan Province and occupies an area of 93,000 square meters (75,000 square meters for construction). This commercial production plant will be equipped with facilities for both drug substance and drug product manufacturing, as well as warehouses. Once the facilities are in full operation, it’s expected that the annual production capacity will be 30 million doses for the recombinant HPV vaccines and 5 million doses for the recombinant polyvalent norovirus vaccine, respectively.